Research sheds light on using multiple CubeSats for in-space servicing and repair missions
As more satellites, telescopes, and other spacecraft are built to be repairable, it will take reliable trajectories for ...
Zacks.com on MSN1d
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
A Mathematician Who Makes the Best of Things
Alessio Figalli studies optimal transport, a field of math that ranges from the movements of clouds to the workings of ...
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
Greetings from the fourth dimension: Scientists glimpse 4D crystal structure using surface wave patterns
Prof. Dan Shechtman of the Technion–Israel Institute of Technology made the discovery that would later earn him the 2011 ...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
The Boston Globe14d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...
Business Insider15d
Vertex Pharmaceuticals (VRTX) Initiated with a Buy at Cantor Fitzgerald
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday ...
Business Insider15d
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to $550.00. Andrew Fein has given his Buy rating due ...
MedCity News15d
Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds
A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...
SiliconANGLE16d
Oracle and Google expand service availability and add cross-region replication for disaster recovery
The new capabilities are for customers who want to use the Autonomous Database while accessing such Google services as Vertex AI and BigQuery. “We have a big user base of enterprise customers ...
WVTM 1316d
FDA approves new pain drug Journavx as opioid alternative
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...